| Patient | Lili Boulanger |
|---|---|
| Date of birth | 1893-08-21 |
| Identifiers | MRN HR-ET025-SYN-TD; SSN (made up) 000-25-7731 |
| Document date | 2026-11-01 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for four months of abdominal pain, diarrhea, fevers, and weight loss. Concerns: Four months of cramping pain low on the right of the abdomen, loose stools up to six times a day and at night, evening fevers, and weight loss; Has been unwell, on and off, since childhood and wants a clear answer and a plan that lets her keep composing and performing. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 1914-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 1915-02-02 to 1915-04-26 | completed | S |
| Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 | One injection every 8 weeks | Subcutaneous route | 1915-04-27 | active | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 1915-02-02 to 1915-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1915-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray before possible immunosuppression and to look for tuberculosis: normal lungs, no hilar nodes, no calcified granulomas | 1915-01-21 to 1915-01-21 | completed | S |
| Ileocolonoscopy with biopsies: deep longitudinal ulcers over the last 15 cm of the terminal ileum; patchy aphthous and serpiginous ulcers in the ascending and transverse colon with normal mucosa between; rectum spared; ileocecal valve patulous, not stenosed; SES-CD 14. Biopsies: chronic active ileitis and colitis with crypt architectural distortion and a few small non-caseating granulomas; acid-fast stain negative, TB PCR (Xpert MTB/RIF) negative; mycobacterial culture sent | 1915-01-23 to 1915-01-23 | completed | S |
| MR enterography: 18 cm of terminal ileal wall thickening (7 mm) with mucosal hyperenhancement and the comb sign; no stricture with upstream dilation, no fistula, abscess, or necrotic lymph nodes; no ascites; ascending colon wall thickening | 1915-01-26 to 1915-01-26 | completed | S |
| Baseline bone density scan (DXA): lumbar spine Z-score -1.4, femoral neck Z-score -1.1, within the expected range for age | 1915-01-28 to 1915-01-28 | completed | S |
| Follow-up ileocolonoscopy eight months into risankizumab: healed ileal ulcers with a few small aphthae and scarring; colon healed; SES-CD 2 (endoscopic response, near remission); no stricture | 1915-10-05 to 1915-10-05 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1914-10-20 | Influenza vaccine, 1914-1915 season | completed | S |
| 1905-09-12 | Tdap vaccine | completed | S |
| 1915-01-28 | Pneumococcal conjugate vaccine PCV20, before immunosuppression | completed | S |
| 1915-01-28 | Recombinant zoster vaccine, dose 1 of 2, before immunosuppression | completed | S |
| 1915-01-28 | Hepatitis B vaccine, adult booster dose (infant series, anti-HBs below 10 mIU/mL) | completed | S |
| 1915-04-27 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 1915-10-19 | Influenza vaccine, 1915-1916 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1895 | Pneumonia at about two years old, described as bronchial pneumonia, with frail health afterwards | D (CLM-0003) |
| Early 1915 | Headaches, loss of appetite, fever, and symptoms resembling colitis and appendicitis, with much time in bed | D (CLM-0007) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Four months of cramping pain low on the right of the abdomen, loose stools up to six times a day and at night, evening fevers, and weight loss | active | S |
| Has been unwell, on and off, since childhood and wants a clear answer and a plan that lets her keep composing and performing | active | S |
Most recent measures: Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1915-10-19; Hemoglobin [Mass/volume] in Blood 13.1 on 1915-08-03; MCV [Entitic mean volume] in Red Blood Cells by Automated count 83 on 1915-04-27; Leukocytes [#/volume] in Blood by Automated count 9.4 on 1915-04-13; Platelets [#/volume] in Blood by Automated count 452 on 1915-01-19; C reactive protein [Mass/volume] in Serum or Plasma 11 on 1915-04-13; Calprotectin [Mass/mass] in Stool 42 on 1915-08-03; Albumin [Mass/volume] in Serum or Plasma 4.3 on 1915-08-03; Ferritin [Mass/volume] in Serum or Plasma 72 on 1915-08-03; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 340 on 1915-08-03; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 1915-04-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1915-04-13; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1915-04-27; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 1915-04-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1915-08-03; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 on 1915-03-02; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1915-04-27; DXA Lumbar spine [Z-score] Bone density -1.4 on 1915-01-28; DXA Femur [Z-score] Bone density -1.1 on 1915-01-28; Phosphate [Mass/volume] in Serum or Plasma 3 on 1915-03-02; Potassium [Moles/volume] in Serum or Plasma 3.4 on 1915-04-13; Total score [AUDIT-C] 0 on 1915-10-19 [S]
Strengths and supports: Supports: close friends and fellow musicians; her teachers at the conservatory [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | resolved | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
| Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | A08.11 | S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1915-01-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | {score} | S | ||
| 1915-01-19 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1915-01-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 76 | fL | 80-100 fL | Low | S |
| 1915-01-19 | Leukocytes [#/volume] in Blood by Automated count | 9.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1915-01-19 | Platelets [#/volume] in Blood by Automated count | 452 | 10*3/uL | 150-400 10*3/uL | High | S |
| 1915-01-19 | C reactive protein [Mass/volume] in Serum or Plasma | 38 | mg/L | <=5 mg/L | High | S |
| 1915-01-19 | Calprotectin [Mass/mass] in Stool | 1240 | ug/g | <=50 ug/g | High | S |
| 1915-01-19 | Albumin [Mass/volume] in Serum or Plasma | 3.3 | g/dL | 3.5-5 g/dL | Low | S |
| 1915-01-19 | Ferritin [Mass/volume] in Serum or Plasma | 9 | ng/mL | 15-150 ng/mL | Low | S |
| 1915-01-19 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 310 | pg/mL | 200-900 pg/mL | Normal | S |
| 1915-01-19 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 18 | ng/mL | 30-100 ng/mL | Low | S |
| 1915-01-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 16 | U/L | <=33 U/L | Normal | S |
| 1915-01-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | <=32 U/L | Normal | S |
| 1915-01-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 1915-01-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1915-01-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 1915-01-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | <=33 U/L | Normal | S |
| 1915-01-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=32 U/L | Normal | S |
| 1915-01-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | <=1.2 mg/dL | Normal | S |
| 1915-01-28 | DXA Lumbar spine [Z-score] Bone density | -1.4 | {Z-score} | A Z-score of -2.0 or below is below the expected range for age | Normal | S |
| 1915-01-28 | DXA Femur [Z-score] Bone density | -1.1 | {Z-score} | A Z-score of -2.0 or below is below the expected range for age | Normal | S |
| 1915-03-02 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1915-03-02 | C reactive protein [Mass/volume] in Serum or Plasma | 8 | mg/L | <=5 mg/L | High | S |
| 1915-03-02 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 1915-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=33 U/L | Normal | S |
| 1915-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | <=32 U/L | Normal | S |
| 1915-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | <=1.2 mg/dL | Normal | S |
| 1915-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1915-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1915-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 1915-04-27 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1915-04-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 83 | fL | 80-100 fL | Normal | S |
| 1915-04-27 | Ferritin [Mass/volume] in Serum or Plasma | 86 | ng/mL | 15-150 ng/mL | Normal | S |
| 1915-04-27 | C reactive protein [Mass/volume] in Serum or Plasma | 3 | mg/L | <=5 mg/L | Normal | S |
| 1915-04-27 | Calprotectin [Mass/mass] in Stool | 210 | ug/g | <=50 ug/g | High | S |
| 1915-04-27 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1915-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | <=33 U/L | Normal | S |
| 1915-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | <=32 U/L | Normal | S |
| 1915-04-27 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | <=1.2 mg/dL | Normal | S |
| 1915-04-27 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1915-08-03 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 1915-08-03 | Ferritin [Mass/volume] in Serum or Plasma | 72 | ng/mL | 15-150 ng/mL | Normal | S |
| 1915-08-03 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 340 | pg/mL | 200-900 pg/mL | Normal | S |
| 1915-08-03 | C reactive protein [Mass/volume] in Serum or Plasma | 2 | mg/L | <=5 mg/L | Normal | S |
| 1915-08-03 | Calprotectin [Mass/mass] in Stool | 42 | ug/g | <=50 ug/g | Normal | S |
| 1915-08-03 | Albumin [Mass/volume] in Serum or Plasma | 4.3 | g/dL | 3.5-5 g/dL | Normal | S |
| 1915-08-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1915-04-13 | Leukocytes [#/volume] in Blood by Automated count | 9.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1915-04-13 | C reactive protein [Mass/volume] in Serum or Plasma | 11 | mg/L | <=5 mg/L | High | S |
| 1915-04-13 | Potassium [Moles/volume] in Serum or Plasma | 3.4 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 1915-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 1915-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | <=33 U/L | Normal | S |
| 1915-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1915-10-19 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1915-01-19 | Body height | 160 | cm | S |
| 1915-01-19 | Body weight | 45 | kg | S |
| 1915-01-19 | Body mass index (BMI) [Ratio] | 17.6 | kg/m2 | S |
| 1915-01-19 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1915-01-19 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1915-01-19 | Heart rate | 96 | /min | S |
| 1915-01-19 | Respiratory rate | 16 | /min | S |
| 1915-01-19 | Body temperature | 37.6 | Cel | S |
| 1915-01-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-01-28 | Body height | 160 | cm | S |
| 1915-01-28 | Body weight | 44.8 | kg | S |
| 1915-01-28 | Body mass index (BMI) [Ratio] | 17.5 | kg/m2 | S |
| 1915-01-28 | Systolic blood pressure | 102 | mm[Hg] | S |
| 1915-01-28 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1915-01-28 | Heart rate | 92 | /min | S |
| 1915-01-28 | Respiratory rate | 16 | /min | S |
| 1915-01-28 | Body temperature | 37.4 | Cel | S |
| 1915-01-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-03-02 | Body height | 160 | cm | S |
| 1915-03-02 | Body weight | 46.4 | kg | S |
| 1915-03-02 | Body mass index (BMI) [Ratio] | 18.1 | kg/m2 | S |
| 1915-03-02 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1915-03-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1915-03-02 | Heart rate | 84 | /min | S |
| 1915-03-02 | Respiratory rate | 14 | /min | S |
| 1915-03-02 | Body temperature | 36.8 | Cel | S |
| 1915-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-04-27 | Body height | 160 | cm | S |
| 1915-04-27 | Body weight | 48.4 | kg | S |
| 1915-04-27 | Body mass index (BMI) [Ratio] | 18.9 | kg/m2 | S |
| 1915-04-27 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1915-04-27 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1915-04-27 | Heart rate | 76 | /min | S |
| 1915-04-27 | Respiratory rate | 14 | /min | S |
| 1915-04-27 | Body temperature | 36.7 | Cel | S |
| 1915-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-08-03 | Body height | 160 | cm | S |
| 1915-08-03 | Body weight | 50.6 | kg | S |
| 1915-08-03 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1915-08-03 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1915-08-03 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1915-08-03 | Heart rate | 72 | /min | S |
| 1915-08-03 | Respiratory rate | 14 | /min | S |
| 1915-08-03 | Body temperature | 36.6 | Cel | S |
| 1915-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-04-13 | Body height | 160 | cm | S |
| 1915-04-13 | Body weight | 46.9 | kg | S |
| 1915-04-13 | Body mass index (BMI) [Ratio] | 18.3 | kg/m2 | S |
| 1915-04-13 | Systolic blood pressure | 98 | mm[Hg] | S |
| 1915-04-13 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 1915-04-13 | Heart rate | 98 | /min | S |
| 1915-04-13 | Respiratory rate | 16 | /min | S |
| 1915-04-13 | Body temperature | 37.7 | Cel | S |
| 1915-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1915-10-19 | Body height | 160 | cm | S |
| 1915-10-19 | Body weight | 51.4 | kg | S |
| 1915-10-19 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1915-10-19 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1915-10-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1915-10-19 | Heart rate | 70 | /min | S |
| 1915-10-19 | Respiratory rate | 14 | /min | S |
| 1915-10-19 | Body temperature | 36.6 | Cel | S |
| 1915-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1915-01-19 | Primary care visit for four months of abdominal pain, diarrhea, fevers, and weight loss | finished | S |
| 1915-01-28 | Diagnosis of Crohn disease with intestinal tuberculosis excluded; inflammatory bowel disease consultation the same day | finished | S |
| 1915-03-02 | Review at week 4 of risankizumab, on the day of the second induction infusion | finished | S |
| 1915-04-27 | Review at week 12, the first maintenance dose of risankizumab | finished | S |
| 1915-08-03 | Six-month review on maintenance risankizumab | finished | S |
| 1915-04-13 | Same-day sick visit for vomiting and diarrhea on risankizumab | finished | S |
| 1915-10-19 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Workup for suspected inflammatory bowel disease: blood count, CRP, albumin, iron studies, vitamin B12 and D, fecal calprotectin, stool tests for Clostridioides difficile and enteric pathogens, celiac serology, a pregnancy test, ileocolonoscopy with biopsies, and MR enterography | completed | GL-ACG-CD-2025, GL-ECCO-ESGAR-2019 | S |
| Exclude intestinal tuberculosis before any steroid or immunosuppressive drug: interferon-gamma release assay, chest X-ray, and ileal and colonic biopsies for acid-fast stain, TB PCR, and mycobacterial culture; with hepatitis B, hepatitis C, HIV, measles, and varicella serology before treatment | completed | GL-ECCO-INF-2026, GL-ACG-CD-2025 | S |
| Gastroenterology (inflammatory bowel disease) consultation once the endoscopy and imaging are done, to confirm the diagnosis and choose treatment with her | completed | GL-ACG-CD-2025, GL-AGA-CD-2021 | S |
| Nutrition: dietitian assessment, small frequent meals with oral nutritional supplements, and weight at every visit | completed | GL-ECCO-CD-2024, GL-ACG-PREV-2025 | S |
| Mood, anxiety, and work: PHQ-9 and GAD-7 at intervals, IBD psychology if needed, and a practical plan for composing and performing during treatment | completed | GL-ACG-PREV-2025 | S |
| Risankizumab 600 mg intravenously at weeks 0, 4, and 8, then 360 mg subcutaneously every 8 weeks, chosen with her as early advanced therapy; liver enzymes and bilirubin at baseline and through at least week 12; a short prednisone bridge tapered over eight weeks; no live vaccines | completed | GL-ACG-CD-2025, GL-AGA-CD-2021, GL-ECCO-CD-2024, GL-FDA-RISANKIZUMAB-2026 | S |
| Vaccines before immunosuppression: PCV20, recombinant zoster vaccine in two doses, a hepatitis B booster with an antibody check one to two months later, and influenza and COVID-19 vaccines each season; live vaccines not needed because she is immune to measles and varicella | completed | GL-ACG-PREV-2025, GL-CDC-IMZ-2026, GL-ECCO-INF-2026 | S |
| Iron, vitamin D, and bone: one intravenous ferric derisomaltose infusion, vitamin D3 daily, calcium while on prednisone, baseline DXA, and weight-bearing exercise | completed | GL-ACG-PREV-2025, GL-ECCO-CD-2024 | S |
| Treat to target: symptoms and CRP at every visit, fecal calprotectin at about three and six months, and ileocolonoscopy at six to twelve months | completed | GL-STRIDE-2021, GL-ACG-CD-2025 | S |
| Contraception, fertility, and pregnancy planning: effective contraception while the disease is active; plan pregnancy after three to six months of steroid-free remission, with a preconception review; continue the biologic in pregnancy after discussing the limited data for risankizumab; folic acid before conception | completed | GL-PREG-IBD-2025, GL-FDA-RISANKIZUMAB-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Reach a diagnosis, with tuberculosis excluded, within two weeks | 1915-01-28 | completed | Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending | S |
| Steroid-free clinical remission by week 12 to 16 of treatment | 1915-04-27 | completed | Harvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended | S |
| Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months | 1915-10-05 | completed | CRP 2 mg/L and calprotectin 42 ug/g at six months; SES-CD 14 to 2 at eight months | S |
| Regain weight to a BMI of 19 or more and correct iron and vitamin D | 1915-08-03 | completed | Weight 50.6 kg (BMI 19.8); hemoglobin 13.1, ferritin 72, vitamin D 34 | S |
| Perform her March concert and keep composing through treatment | 1915-04-27 | completed | Composing most mornings; the concert went ahead in late March with a plan for bathroom access | S |